

PTO/SB/08B(10-01)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO Complete if Known 09/666,430 Application Number INFORMATION DISCLOSURE September 21, 2000 Filing Date STATEMENT BY APPLICANT Rea et al. First Named Inventor 1644 Group Art Unit (use as many sheets as necessary) **Examiner Name** G. Ewoldt 2183-4205 HIS Attorney Docket Number

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	1	AHFS Drug Laformation 91, p. 1810.	
	2	Molecular Biology of the Cell, 1989, pp. 1044-48."	
	3	Remington's Pharmaceutical Sciences, 1985, pp. 958-72, Mack Publishing Company, USA.	
	4	Fujikawa v. Wattanasin, 93 F.3d. 1559, August 28, 1996, Decided.	
	5	Dictionary of Genetics, 1997, pp. 14, 332, Oxford University Press, USA.	
PSZ	6	CRONSTEIN et al., A mechanism for the antiinflammatory effects of conticosteroids: The glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1, Proc. Natl. Acad. Sci., November 1992, pp. 9991-95, Vol. 89, USA.	
1	7	GRETEN et al., Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19-specific CD8+ T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients, Proc. Natl. Acad. Sci., June 1998, pp. 7568-7573, Vol. 95, USA.	
1	8	HANCOCK et al., Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection, Proc. Natl. Acad. Sci., November 1996, pp. 13967-72, Vol. 93, USA.	
	9	KAMPGEN et al., Class II major histocompatibility complex molecules of murine dendritic cells: Synthesis, sialylation of invariant chain, and antigen processing capacity are down-regulated upon culture, Proc. Natl. Acad. Sci., April 1991, pp. 3014-18, Vol. 88, USA.	
	10	NICHOLSON et al., Heteroclitic proliferative responses and changes in cytokine profile induced by altered peptides: Implications for autoimmunity, Proc. Natl. Acad. Sci. January 1998, pp. 264-69, Vol. 95, USA.	
128	11	STEEME et al., T lymphocytes from human atherosclerotic plaques recognize oxidized low denisty lipoprotein, Proc. Natl. Acad. Sci, April 1995, pp. 3893-97, Vol. 92, USA.	
	12	TAN, Glueocorticoids - Disease Mechanism II: Inflammation (last modified 3-7-03) ">http://www.stanford.edu/group/hopes/treatmts/antinflam/i>.	

Examiner	1385 12/22/04	Date Considered	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.